1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY |
|||||||||||
|
UNI - EN REPORT No |
25 | / |
2026 |
|
||||||
Date of issue: |
2026-05-14 |
||||||||||
Short name of the issuer |
|||||||||||
KRKA |
|||||||||||
Subject |
|||||||||||
Unaudited Interim Report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2026 |
|||||||||||
Official market - legal basis |
|||||||||||
Art. 56. 1. 2 of Act on Public Offering |
|||||||||||
Unofficial market - legal basis |
|||||||||||
Contents of the report: |
|||||||||||
Based on Article 26 of the Rules of the Ljubljana Stock Exchange, the company Krka, d. d., Novo mesto publishes the Unaudited interim Report of the Krka Group and Krka, d. d., Novo mesto for the first quarter of 2026. The report will be published on the Company's website (www.krka.biz) from 14 May 2026 onwards, for a minimum period of 5 years. |
|||||||||||
Annexes |
|||||||||||
File |
Description |
||||||||||
Press release |
|||||||||||
Q1 2026 Unaudited Interim Report of the Krka Group and Krka Company.pdf |
Q1 2026 Unaudited Interim Report of the Krka Group and Krka Company |
||||||||||
KRKA, TOVARNA ZDRAVIL D.D. |
|||||||||||||
(fullname of the issuer) |
|||||||||||||
KRKA |
Farmaceutyczny (far) |
||||||||||||
(short name of the issuer) |
(sector according to clasification of the WSE in Warsow) |
||||||||||||
8501 |
Nove Mesto |
||||||||||||
(post code) |
(city) |
||||||||||||
Smarjeska |
6 | ||||||||||||
(street) |
(number) |
||||||||||||
+386 7 331 21 11 |
+386 7 332 15 37 |
||||||||||||
(phone number) |
(fax) |
||||||||||||
(e-mail) |
(web site) |
||||||||||||
nie dotyczy |
|||||||||||||
(NIP) |
(REGON) |
||||||||||||
SIGNATURE OF PERSONS REPRESENTING THE COMPANY |
|||||
Date |
Name |
Position / Function |
Signature |
||
2026-05-14 |
Jože Colarič |
President of the Management Board and CEO |
|||
